SCHEMBL4579585

SCHEMBL4579585

O=C(O)CCC1CCC(=O)N1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB1 P05556 2/20 0.42
ITGA5 P08648 2/20 0.42
ITGB3 P05106 1/20 0.42
ITGB2 P05107 1/20 0.42
ITGAV P06756 1/20 0.42
ITGA2B P08514 1/20 0.42
ITGB5 P18084 1/20 0.42
ITGAL P20701 1/20 0.42
FOLH1 Q04609 1/20 0.39
MGLL Q99685 3/20 0.38
NPSR1 Q6W5P4 1/20 0.37
FFAR4 Q5NUL3 1/20 0.36
TDP1 Q9NUW8 4/20 0.34
ABL1 P00519 2/20 0.33
IDE P14735 2/20 0.33
RIN1 Q13671 2/20 0.33
PPARG P37231 1/20 0.33
NR2E3 Q9Y5X4 1/20 0.33
NCOR2 Q9Y618 1/20 0.33
PDCD1LG2 Q9BQ51 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31124620 1.00 ITGB1 (0.42) ITGB1ITGA5ITGB3ITGB2ITGAV
SCHEMBL31124633 1.00 ITGB1 (0.42) ITGB1ITGA5ITGB3ITGB2ITGAV
SCHEMBL10650169 0.98 ITGB1 (0.41) ITGB1ITGA5ITGB3ITGB2ITGAV
SCHEMBL10640864 0.92 FFAR4 (0.42) ITGB1ITGA5ITGB3ITGB2ITGAV
SCHEMBL25255061 0.89 ITGB1 (0.40) ITGB1ITGA5ITGB3ITGB2ITGAV
SCHEMBL197943 0.89 ITGB1 (0.40) ITGB1ITGA5ITGB3ITGB2ITGAV
SCHEMBL2582193 0.87 TDP1 (0.45) ITGB1ITGA5ITGB3ITGB2ITGAV
SCHEMBL27353938 0.83 MGLL (0.37) ITGB1ITGA5ITGB3ITGB2ITGAV
SCHEMBL10645217 0.83 GAA (0.38) MGLLCD274IRAK4
SCHEMBL10650173 0.81 MGLL (0.37) ITGB1ITGA5ITGB3ITGB2ITGAV

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0238088-B1 IMPROVED PROCESS FOR THE PREPARATION OF DIHYDRO-1H-PYRROLIZINE-3,5-(2H,6H)-DIONE WARNER-LAMBERT COMPANY (US) 1990-10-31 EP claimed
EP-0095278-B1 5-OXO-2-PYRROLIDINEPROPANOIC ACID DERIVATIVES AND THEIR PRODUCTION WARNER-LAMBERT COMPANY (US) 1988-11-30 EP claimed
EP-0164852-B1 1-(SUBSTITUTED-ARYL)-DIHYDRO-1H-PYRROLIZINE-3,5-(2H,6H-)DIONES, A PROCESS FOR PRODUCING THE COMPOUNDS AND A PHARMACEUTICAL COMPOSITION COMPRISING THE COMPOUNDS WARNER-LAMBERT COMPANY (US) 1988-07-06 EP claimed
EP-0238088-A2 Improved process for the preparation of dihydro-1H-pyrrolizine-3,5-(2H,6H)-dione WARNER-LAMBERT COMPANY (US) 1987-09-23 EP claimed
US-4663464-A Process for the preparation of dihydro-1H-pyrrolizine-3,5-(2H,6H)-dione WARNER-LAMBERT COMPANY (US) 1987-05-05 US claimed
EP-0164852-A1 1-(Substituted-aryl)-Dihydro-1H-pyrrolizine-3,5-(2H,6H-)diones, a process for producing the compounds and a pharmaceutical composition comprising the compounds WARNER-LAMBERT COMPANY (US) 1985-12-18 EP claimed
US-11981661-B2 Heterocyclic compounds HOFFMANN-LA ROCHE INC. (US) 2024-05-14 US disclosed
EP-4208456-A1 HETEROCYCLIC COMPOUNDS F. Hoffmann-La Roche AG (CH) 2023-07-12 EP disclosed
CN-115989228-A Heterocyclic compounds 豪夫迈·罗氏有限公司 2023-04-18 CN disclosed
US-20220098176-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2022-03-31 US disclosed
US-8445081-B2 Polarizing plate protective film, polarizing plate and liquid crystal display device KONICA MINOLTA OPTO, INC. (JP) 2013-05-21 US disclosed
US-7414071-B2 Methods of treatment with selective EP4 receptor agonists PFIZER INC. (US) 2008-08-19 US disclosed
US-7414071-B2 Methods of treatment with selective EP4 receptor agonists PFIZER INC. (US) 2008-08-19 US disclosed
EP-0110575-A1 1-Aroyl-5-oxo-2-pyrrolidinepropanoic acids and related esters WARNER-LAMBERT COMPANY (US) 1984-06-13 EP disclosed
US-4452990-A TREATMENT OF SENILITY, AMNESIA AND MOTIVATION WARNER-LAMBERT COMPANY (US) 1984-06-05 US disclosed
EP-0095278-A2 5-Oxo-2-pyrrolidinepropanoic acid derivatives and their production WARNER-LAMBERT COMPANY (US) 1983-11-30 EP disclosed
EP-0095278-A2 5-Oxo-2-pyrrolidinepropanoic acid derivatives and their production WARNER-LAMBERT COMPANY (US) 1983-11-30 EP disclosed
EP-0095278-A2 5-Oxo-2-pyrrolidinepropanoic acid derivatives and their production WARNER-LAMBERT COMPANY (US) 1983-11-30 EP disclosed
US-4372966-A TREATMENT OF SENILITY, ENHANCING MEMORY, REVERSAL OF AMNESIA CAUSED BY ELECTRIC SHOCK WARNER-LAMBERT COMPANY (US) 1983-02-08 US disclosed
EP-0048132-A2 The use of dihydro-1H-pyrrolizine-3,5(2H,6H)-dione as a cognition activator, pharmaceutical compositions containing that compound, and the production of such compositions WARNER-LAMBERT COMPANY (US) 1982-03-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220098176-A1 HETEROCYCLIC COMPOUNDS CBR3, BRIX1, CCNY ITGB1 3738/4885ITGA5 3646/4885ITGB3 3207/4885
US-11981661-B2 Heterocyclic compounds CBR3, BRIX1, CCNY ITGB1 3738/4885ITGA5 3646/4885ITGB3 3207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.